Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594823 | 0.88 | CA2 (0.63) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL2103432 | 0.82 | SMN1; SMN2 (0.58) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL3838426 | 0.82 | L3MBTL1 (0.58) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL6534172 | 0.81 | AOC3 (0.50) | L3MBTL1CNR2TSHRPOLB | |
| SCHEMBL14253619 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL27372293 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL21033829 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL2103431 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL15672905 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CA2CNR2CNR1ALDH1A1 | |
| SCHEMBL3837668 | 0.79 | CNR2 (0.71) | L3MBTL1CNR2CNR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| CN-104193725-A | ORGANIC COMPOUNDS | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| CN-102076665-B | Organic compounds | NOVARTIS AG | 2014-09-03 | — | — | CN | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791141-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-8030334-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| CN-102076665-A | Organic compounds | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | L3MBTL1 4840/4885CA2 559/4885CNR2 1313/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | L3MBTL1 4840/4885CA2 559/4885CNR2 1313/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | L3MBTL1 4727/4885CA2 896/4885CNR2 1488/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | L3MBTL1 4727/4885CA2 896/4885CNR2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.